USC Schaeffer on Mythryl: “A prolonged vacancy atop the FDA could mean delayed work on new…”

@schaeffer.usc.edu

A prolonged vacancy atop the FDA could mean delayed work on new treatments until there's greater policy clarity, USC Schaeffer's @profgenkanter.bsky.social tells Pharma Voice. “Transition delays and really, any uncertainty in leadership, are not good for the industry and not good for the public."

pharmavoice.comWhy the FDA’s top spot could sit empty for monthsMultiple factors could get in the way of confirming a new commissioner before the midterm elections, experts said, leaving the agency’s long-term initiatives in limbo.

23/7/26, 5:09 pm1 repost3 likes

Post